씨엔알리서치

359090KOSDAQ그외 기타 전문, 과학 및 기술 서비스업

60.8 / 100

Reference Date: 2026-04-13

Financial Score29.5 / 40

News Sentiment16.3 / 25

Momentum6.0 / 20

Disclosure9.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but Operating Profit is on a declining trend. Slightly down 3.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

CNR Research, established in 1997 as Korea's first CRO, provides clinical trial services for drug development, including Phase I-III trials for regulatory approval and post-market studies (PMS/Phase IV). It maintains the top position among domestic CROs by revenue in 2023 and aims to expand globally through IT solution development and oncology trial expertise.

Number of Employees

522people

Average Salary

58.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

17.38Industry Average 59.138.0Point

Half of industry avg (excellent)

PBR

0.94Industry Average 1.947.0Point

Half of industry avg (excellent)

ROE

2.15Industry Average 1.534.0Point

In line with industry avg

Debt Ratio

5.27Industry Average 16.096.5Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼51.8% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 7.9% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 2Neutral 0Negative 0Average Sentiment Score 80

Positive
씨엔알리서치, 대웅제약과 다국가 대규모 3상 임상시험 착수
씨엔알리서치는 대웅제약과 약 115억원 규모의 다국가 3상 임상시험 계약을 체결하고 한국과 인도네시아에서 동시에 프로젝트를 총괄 수행합니다.
Positive
씨엔알리서치,인도네시아 지사 설립…"아세안 시장 공략 본격화"
씨엔알리서치는 인도네시아에 지사를 설립하고 현지 임상시험 운영 기반을 마련하여 동남아 임상 네트워크를 확대하고 '아시안 글로벌 CRO'로의 도약을 본격화하고 있습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 782Won52-week high 1,10252-week low 740

1-month return2.0Point

1m -3.93% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

8 totalPositive 1Neutral 6Negative 1

Negative불성실공시법인지정예고 (공시불이행 1건, 공시변경 1건)2026-04-10
Positive단일판매ㆍ공급계약체결2026-03-30
Neutral주주명부폐쇄기간또는기준일설정2026-03-25
Neutral주주총회소집결의 (임시주주총회)2026-03-25
Neutral주식병합결정2026-03-25